View Future GrowthTdspharm 과거 순이익 실적과거 기준 점검 4/6Tdspharm은 연평균 8.1%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 수입이 12% 증가했습니다. 매출은 연평균 19.6%의 비율로 증가했습니다. Tdspharm의 자기자본이익률은 11.5%이고 순이익률은 16.6%입니다.핵심 정보8.10%순이익 성장률-123.13%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률11.32%매출 성장률19.57%자기자본이익률11.51%순이익률16.62%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트분석 기사 • Nov 26Why Tdspharm's (KOSDAQ:464280) Shaky Earnings Are Just The Beginning Of Its ProblemsA lackluster earnings announcement from Tdspharm Co., Ltd. ( KOSDAQ:464280 ) last week didn't sink the stock price. Our...모든 업데이트 보기Recent updatesValuation Update With 7 Day Price Move • Jun 24Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩5,910, the stock trades at a trailing P/E ratio of 6.5x. Average trailing P/E is 10x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 47% over the past year.Valuation Update With 7 Day Price Move • Jun 01Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩7,010, the stock trades at a trailing P/E ratio of 7.7x. Average trailing P/E is 11x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 38% over the past year.New Risk • Mar 21New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 60% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (60% accrual ratio). Minor Risk Market cap is less than US$100m (₩50.1b market cap, or US$33.3m).Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩8,500, the stock trades at a trailing P/E ratio of 14.3x. Average trailing P/E is 17x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 37% over the past year.공고 • Feb 10Tdspharm Co., Ltd., Annual General Meeting, Mar 25, 2026Tdspharm Co., Ltd., Annual General Meeting, Mar 25, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 253, pangyo-ro, bundang-gu, gyeonggi-do, seongnam South Korea분석 기사 • Jan 29Risks To Shareholder Returns Are Elevated At These Prices For Tdspharm Co., Ltd. (KOSDAQ:464280)With a price-to-earnings (or "P/E") ratio of 16.8x Tdspharm Co., Ltd. ( KOSDAQ:464280 ) may be sending bearish signals...New Risk • Nov 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Market cap is less than US$100m (₩58.1b market cap, or US$39.5m).Valuation Update With 7 Day Price Move • Nov 28Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₩10,500, the stock trades at a trailing P/E ratio of 17.7x. Average trailing P/E is 15x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 37% over the past year.분석 기사 • Nov 26Why Tdspharm's (KOSDAQ:464280) Shaky Earnings Are Just The Beginning Of Its ProblemsA lackluster earnings announcement from Tdspharm Co., Ltd. ( KOSDAQ:464280 ) last week didn't sink the stock price. Our...Buy Or Sell Opportunity • Jul 30Now 22% overvaluedOver the last 90 days, the stock has fallen 9.9% to ₩11,000. The fair value is estimated to be ₩9,047, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 15% over the last year. Earnings per share has declined by 35%.Buy Or Sell Opportunity • Jul 15Now 25% overvaluedOver the last 90 days, the stock has fallen 8.2% to ₩11,270. The fair value is estimated to be ₩9,047, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 15% over the last year. Earnings per share has declined by 35%.공고 • Feb 08Tdspharm Co., Ltd., Annual General Meeting, Mar 25, 2025Tdspharm Co., Ltd., Annual General Meeting, Mar 25, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 253, pangyo-ro, bundang-gu, gyeonggi-do, seongnam South KoreaNew Risk • Sep 23New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩120.8b (US$90.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shares are highly illiquid. Minor Risk Market cap is less than US$100m (₩120.8b market cap, or US$90.4m).매출 및 비용 세부 내역Tdspharm가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이KOSDAQ:A464280 매출, 비용 및 순이익 (KRW Millions)날짜매출순이익일반관리비연구개발비31 Mar 2630,4115,0552,75065431 Dec 2527,6214,2752,77366630 Sep 2524,5613,2812,97370230 Jun 2522,9442,6683,14467631 Mar 2525,4343,2753,09665931 Dec 2427,5193,7183,08262230 Sep 2430,8074,6632,90752031 Mar 2429,9704,3922,38745831 Dec 2330,0494,6882,23344131 Dec 2225,5883,4561,69147931 Dec 2119,8202,0631,16835631 Dec 2018,0231,3511,01943731 Dec 1919,2139991,22145531 Dec 1817,750-8481,57333931 Dec 1715,5201,6551,49035731 Dec 1613,8531,1721,217687양질의 수익: A464280의 비현금 수익 수준이 높습니다.이익 마진 증가: A464280의 현재 순 이익률 (16.6%)은 지난해 (12.9%)보다 높습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: A464280의 수익은 지난 5년 동안 연평균 8.1% 증가했습니다.성장 가속화: 지난 1년간 A464280 의 수익 증가율(54.3%)은 연간 평균(8.1%)을 초과합니다.수익 대 산업: A464280의 지난 1년 수익 증가율(54.3%)은 Pharmaceuticals 업계의 28.8%를 상회했습니다.자기자본이익률높은 ROE: A464280의 자본 수익률(11.5%)은 낮음으로 평가됩니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/21 22:15종가2026/07/21 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Tdspharm Co., Ltd.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
분석 기사 • Nov 26Why Tdspharm's (KOSDAQ:464280) Shaky Earnings Are Just The Beginning Of Its ProblemsA lackluster earnings announcement from Tdspharm Co., Ltd. ( KOSDAQ:464280 ) last week didn't sink the stock price. Our...
Valuation Update With 7 Day Price Move • Jun 24Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩5,910, the stock trades at a trailing P/E ratio of 6.5x. Average trailing P/E is 10x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 47% over the past year.
Valuation Update With 7 Day Price Move • Jun 01Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩7,010, the stock trades at a trailing P/E ratio of 7.7x. Average trailing P/E is 11x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 38% over the past year.
New Risk • Mar 21New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 60% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (60% accrual ratio). Minor Risk Market cap is less than US$100m (₩50.1b market cap, or US$33.3m).
Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩8,500, the stock trades at a trailing P/E ratio of 14.3x. Average trailing P/E is 17x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 37% over the past year.
공고 • Feb 10Tdspharm Co., Ltd., Annual General Meeting, Mar 25, 2026Tdspharm Co., Ltd., Annual General Meeting, Mar 25, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 253, pangyo-ro, bundang-gu, gyeonggi-do, seongnam South Korea
분석 기사 • Jan 29Risks To Shareholder Returns Are Elevated At These Prices For Tdspharm Co., Ltd. (KOSDAQ:464280)With a price-to-earnings (or "P/E") ratio of 16.8x Tdspharm Co., Ltd. ( KOSDAQ:464280 ) may be sending bearish signals...
New Risk • Nov 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Market cap is less than US$100m (₩58.1b market cap, or US$39.5m).
Valuation Update With 7 Day Price Move • Nov 28Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₩10,500, the stock trades at a trailing P/E ratio of 17.7x. Average trailing P/E is 15x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 37% over the past year.
분석 기사 • Nov 26Why Tdspharm's (KOSDAQ:464280) Shaky Earnings Are Just The Beginning Of Its ProblemsA lackluster earnings announcement from Tdspharm Co., Ltd. ( KOSDAQ:464280 ) last week didn't sink the stock price. Our...
Buy Or Sell Opportunity • Jul 30Now 22% overvaluedOver the last 90 days, the stock has fallen 9.9% to ₩11,000. The fair value is estimated to be ₩9,047, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 15% over the last year. Earnings per share has declined by 35%.
Buy Or Sell Opportunity • Jul 15Now 25% overvaluedOver the last 90 days, the stock has fallen 8.2% to ₩11,270. The fair value is estimated to be ₩9,047, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 15% over the last year. Earnings per share has declined by 35%.
공고 • Feb 08Tdspharm Co., Ltd., Annual General Meeting, Mar 25, 2025Tdspharm Co., Ltd., Annual General Meeting, Mar 25, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 253, pangyo-ro, bundang-gu, gyeonggi-do, seongnam South Korea
New Risk • Sep 23New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩120.8b (US$90.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shares are highly illiquid. Minor Risk Market cap is less than US$100m (₩120.8b market cap, or US$90.4m).